Harvest Steps into Stem Cells
Harvest Technologies, a 14-year-old player in the blood and marrow supply arena, is moving aggressively into the business of selling stem cells therapies for cardiovascular disease.
You may also be interested in...
The global market for orthobiologics, comprised primarily of bone replacement materials, reached almost $2 billion in 2009 and is growing at an overall rate of 7%. Medtronic leads in bone replacement with a 45% market share, but overall growth in orthobiologics may come from emerging segments, particular synthetic and stem-cell based technologies.
Recent research advances and relaxation of government restrictions have opened the stem cell field to product possibilities. Companies developing these potentially revolutionary products must also come up with workable business models. In this issue we profile five emerging contenders: Amorcyte, California Stem Cell, Cardio3 BioSciences, CellDesign and Fate Therapeutics.
More than 40 companies revealed promising research and clinical results at the 2008 Stem Cell Summit in February. Perhaps most impressive was the number of stem cell therapies already in use or tantalizingly close to market launch.